Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice
F Song, H Al-Samkari - Journal of Blood Medicine, 2021 - Taylor & Francis
Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …
[HTML][HTML] Contemporary management of primary immune thrombocytopenia in adults
S Lakshmanan, A Cuker - Journal of Thrombosis and Haemostasis, 2012 - Elsevier
Immune thrombocytopenia (ITP) comprises a syndrome of diverse disorders that have in
common immune‐mediated thrombocytopenia, but that differ with respect to pathogenesis …
common immune‐mediated thrombocytopenia, but that differ with respect to pathogenesis …
Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs
M Witkowski, M Witkowska… - European journal of …, 2019 - Wiley Online Library
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by platelet
destruction and reduced platelet production resulting in decreased platelet level and an …
destruction and reduced platelet production resulting in decreased platelet level and an …
Systematic literature review of treatments used for adult immune thrombocytopenia in the second‐line setting
LC Bylsma, JP Fryzek, K Cetin… - American Journal of …, 2019 - Wiley Online Library
Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic
in adults. Patient management is dependent upon physician judgment and patient …
in adults. Patient management is dependent upon physician judgment and patient …
Current management of immune thrombocytopenia
CE Neunert - Hematology 2013, the American Society of …, 2013 - ashpublications.org
Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from
antibody-mediated destruction of platelets and impaired megakaryocyte platelet production …
antibody-mediated destruction of platelets and impaired megakaryocyte platelet production …
[HTML][HTML] Immune thrombocytopenia (ITP): current limitations in patient management
DR Terrell, CE Neunert, N Cooper, KM Heitink-Pollé… - Medicina, 2020 - mdpi.com
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized
by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet …
by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet …
[HTML][HTML] Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently?
Y Lv, H Shi, H Liu, L Zhou - Frontiers in Immunology, 2022 - frontiersin.org
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder featured by
increased platelet destruction and deficient megakaryocyte maturation. First-line treatments …
increased platelet destruction and deficient megakaryocyte maturation. First-line treatments …
[HTML][HTML] Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment
H Al-Samkari, DJ Kuter - Seminars in thrombosis and …, 2020 - thieme-connect.com
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting
approximately 1 in 20,000 people. Patients typically present with clinically benign …
approximately 1 in 20,000 people. Patients typically present with clinically benign …
Clinical updates in adult immune thrombocytopenia
MP Lambert, TB Gernsheimer - Blood, The Journal of the …, 2017 - ashpublications.org
Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …